LCM
ENTA icon

Laurion Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Laurion Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,287
Closed -$126K – 515
2023
Q3 		$126K Buy
+11,287
New +$182K ﹤0.01% 442
2020
Q3 		– Sell
-8,178
Closed -$411K – 924
2020
Q2 		$411K Buy
+8,178
New +$423K ﹤0.01% 660
2020
Q1 		– Sell
-6,100
Closed -$377K – 842
2019
Q4 		$377K Buy
+6,100
New +$378K ﹤0.01% 732

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Laurion Capital Management's ENTA Position: Q4 2023 in Review

Laurion Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 11,287 shares — an estimated $126K sold.

Laurion Capital Management first reported a position in ENTA in Q4 2019 and held it in 3 quarters. The position peaked at $411K in Q2 2020. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Laurion Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Laurion Capital Management sold 11,287 Enanta Pharmaceuticals shares in Q4 2023, an estimated $126K.
  • Laurion Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Laurion Capital Management's Enanta Pharmaceuticals position peaked at $411K in Q2 2020.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.